Dermata Therapeutics (DRMAW) Competitors $0.01 0.00 (0.00%) (As of 11/5/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends DRMAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ALVO, ACABW, ACABU, BFRIW, and BTMDWShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Alvotech (ALVO), Atlantic Coastal Acquisition Corp. II (ACABW), Atlantic Coastal Acquisition Corp. II (ACABU), Biofrontera (BFRIW), and biote (BTMDW). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Alvotech Atlantic Coastal Acquisition Corp. II Atlantic Coastal Acquisition Corp. II Biofrontera biote 180 Life Sciences (NASDAQ:ATNFW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking. Does the MarketBeat Community favor ATNFW or DRMAW? 180 Life Sciences and Dermata Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/ADermata TherapeuticsN/AN/A Do analysts prefer ATNFW or DRMAW? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ADermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media prefer ATNFW or DRMAW? In the previous week, 180 Life Sciences' average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral Dermata Therapeutics Neutral Which has stronger valuation & earnings, ATNFW or DRMAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ADermata TherapeuticsN/AN/AN/AN/AN/A Is ATNFW or DRMAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Dermata Therapeutics N/A N/A N/A Summary180 Life Sciences and Dermata Therapeutics tied by winning 0 of the 0 factors compared between the two stocks. Ad Porter & CompanyElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration. Watch this new documentary and you’ll discover what Elon knows, Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMAW vs. The Competition Export to ExcelMetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$185.19M$5.25B$8.58BDividend YieldN/A3.48%5.09%4.03%P/E RatioN/A335.57117.8415.89Price / SalesN/A20,064.321,649.1998.02Price / CashN/A11.4734.4331.48Price / BookN/A7.004.794.67Net IncomeN/A-$20.22M$117.16M$223.05M7 Day PerformanceN/A1.81%-0.14%0.44%1 Month PerformanceN/A3.20%6.21%4.71%1 Year PerformanceN/A24.42%35.06%27.26% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMAWDermata TherapeuticsN/A$0.01flatN/AN/A$0.00N/A0.008ATNFW180 Life SciencesN/A$0.01flatN/A+9.0%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.05+28.6%N/A+219.2%$0.00N/A0.002Gap UpAIMDWAinosN/A$0.03flatN/A-93.3%$0.00$65,122.000.0040Positive NewsALVOWAlvotechN/A$3.20+5.3%N/A+115.0%$0.00$306.77M0.004Gap DownALVOAlvotech3.1783 of 5 stars$13.02+0.3%$18.00+38.2%+45.5%$0.00$93.38M-4.911,026News CoverageACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/A-37.3%$0.00N/A0.004Positive NewsACABUAtlantic Coastal Acquisition Corp. IIN/A$12.54flatN/A+19.1%$0.00N/A0.004Positive NewsGap UpBFRIWBiofronteraN/A$0.07-64.6%N/A+300.0%$0.00$35.24M0.0070Gap DownHigh Trading VolumeBTMDWbioteN/A$0.56flatN/A+49.0%$0.00$187.23M0.00N/AGap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ALVO Competitors ACABW Competitors ACABU Competitors BFRIW Competitors BTMDW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRMAW) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
